The 32nd Annual
Cancer Progress Conference
May 4-6, 2021
❝ Inspiring Cancer Progress through engaged stakeholder dialogue ❞
Sign up to get the latest event updates and information.
It is time for everyone to save the date for Cancer Progress! With the success of our 1st virtual event, it is our pleasure to announce our 32nd Annual and 2nd virtual.
With the success of our first virtual conference, we are looking to expand to three days and are considering adding a partnering component.
We are incredibly grateful for the donations we received during Cancer Progress 2020. With your help we raised close to $20,000 and donated to:
Cancer Progress Conference Panels Include...
Climbing the Highest Peak: Targeting PD-1/L1 Failures in Solid Tumors
Multifunctional Soluble Biologics: Binders, Binders Everywhere
Tumor Agnostic Development
Accelerated Development Paths
Endogenous Reprogramming: Anything One Can Do Ex Vivo, Can One Do In Vivo (and Do Better)?
Allogeneic Cell Therapy: Stocking the Shelf Part I (NKs, NKTs)
Allogeneic Cell Therapy: Stocking the Shelf Part II (Traditional T-cells, Gamma-deltas)
Cell Therapy in Solid Tumors: Freedom of the Open Road
Validating New Platforms: Clinical Pain, Commercial Gain
Counterpoint to Engineered Platforms: Less is More
China
Investing in the Emerald City of Oncology Innovation: Platforms & Modalities & Targets, Oh My!
Heme Malignancies Transformed: An Idiosyncratic Comparison of Multiple Myeloma and AML
Let’s Make a Deal in Oncology: What’s Behind the Doors & Who Has the Keys? Value Panel
Battle of the Modalities- The sequel
Cancer Progress 2020 Panel Summaries
As a preview of the good things to expect from Cancer Progress 2021, we’re excited to roll out summaries of select sessions from Cancer Progress 2020, starting with a summary of the panel “Paradigm Shifting Platforms II – Non-IO: Targeting Better, Targeting the Intractable” that highlights the key opportunities and challenges of non-IO targeted approaches and how even they cannot be thought of independently from IO.
Paradigm Shifting Platforms I –IO: Taking IO to the Next Level
Paradigm-shifting platforms II, Non-IO: Targeting Better, Targeting the Intractable
Oncology Modalities Facing Off: Room for Many or One to Rule them All
Since 1989, Cancer Progress is the only oncology conference that invites a discussion of scientific progress within the context of development, regulatory, clinical, commercial and investment perspectives in two days of interactive dialogue. Pivotal topics, frank discussions, vigorous debate, lively audience participation and generous networking throughout the meeting during breaks, luncheons, reception and dinner combine to make this a highly impactful conference.
Our 32nd Annual Meeting on May 4-6, 2021 will provide an unsurpassed learning experience for participants in quality of information, coverage of issues, and value of professional contacts. The quality of the speaking faculty is a major contributor to the popularity and value of this conference.
Testimonials
Good array of opinions and technologies. Well curated
Andrew Allen, MD, PhD, President & CEO
Gritstone OncologyAs I like to say, Cancer Progress is THE BEST non-academic cancer conference out there. Again proving your staggering insight!
Michael G. King, Jr., Entrepreneur in Residence
Fortress Biotech Inc.When we hear all the negatives from the experts on cell therapies and COVID—let’s think of Richard Feynman: “Science is the belief in the ignorance of the experts
Mark Simon, Managing Director
Torreya“Thank you for the opportunity. I felt privileged to be part of a panel composed of stellar leaders within the Oncology space.”
Noemi Rosa
Novartis“I really enjoyed the meeting as usual – great topics and speakers. I look forward to next year’s meeting!”